HC Wainwright Predicts Chimerix’s Q4 Earnings (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRX) – Investment analysts at HC Wainwright lifted their Q4 2024 earnings per share estimates for shares of Chimerix in a research report issued on Wednesday, December 11th. HC Wainwright analyst E. White now expects that the biopharmaceutical company will earn ($0.24) per share for the quarter, up from their previous estimate of ($0.25). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Chimerix’s Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($0.99) EPS.

Other research analysts have also recently issued research reports about the stock. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st. Wedbush restated an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research note on Tuesday.

Chimerix Price Performance

Shares of NASDAQ:CMRX opened at $2.94 on Friday. The firm has a market capitalization of $264.41 million, a PE ratio of -3.13 and a beta of 1.02. Chimerix has a 1 year low of $0.75 and a 1 year high of $3.39. The firm’s 50-day moving average is $1.03 and its two-hundred day moving average is $0.94.

Hedge Funds Weigh In On Chimerix

A number of institutional investors and hedge funds have recently made changes to their positions in CMRX. Marshall Wace LLP acquired a new position in shares of Chimerix during the second quarter worth $137,000. Valeo Financial Advisors LLC lifted its holdings in Chimerix by 566.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 69,505 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 138,098 shares in the last quarter. 45.42% of the stock is owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.